The pathogenic role of Th17 cells in the CNS has received extensive attention on the pathogenesis of autoimmune demyelinating diseases, where their contribution is well established (133), and at least one proof-of-concept study provided evidence that secukinumab, which blocks IL-17A, may reduce lesions in MS patients (134). Here, IL17A is linked to myeloid sarcoma.